You are here

SBIR Phase II: Development of Agents to Promote Cellular Ga-67 (Gallium-67) Uptake

Award Information
Agency: National Science Foundation
Branch: N/A
Contract: 0450618
Agency Tracking Number: 0320485
Amount: $99,999.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: N/A
Timeline
Solicitation Year: N/A
Award Year: 2003
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
325 S.W. Cyber Drive
Bend, OR 97702
United States
DUNS: N/A
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 Takuji Tsukamoto
 Dr
 (541) 385-0355
 taku@chemica.com
Business Contact
 Takuji Tsukamoto
Title: Dr
Phone: (541) 385-0355
Email: taku@chemica.com
Research Institution
N/A
Abstract

This Small Business Innovation Research Phase II project focuses on the development of new pharmaceutical agents to selectively enhance tumor imaging using gallium 67. A photo-degradation product of nifedipine, nitrosipine, has been found to selectively enhance the uptake of Ga67 by tumor cells. A specific derivative of nitrosipine has an even better selective uptake of the radioactive imaging agent. This project will synthesize and test other nitrosipine derivatives and determine the efficacy of Ga67 uptake in animal models using these complexing agents. The commercial application of this technology is in the area of diagnostic imaging. The use of Ga67 in tumor imaging is currently very limited due to poor selectivity of the agent for tumor cells. Enhanced uptake in tumor cells relative to normal cells would expand the types of tumors that could be effectively imaged and possibly replace the more costly and complex PET scan imaging using radioactive fluorinated sugars.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government